With a focus on innovation and precision, these novel ADCs are at the forefront of a new era in targeted cancer therapy, holding the potential to improve outcomes for patients with HER2-positive and HER2-Low breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.